Abstract
Even before the discovery of the mutant htt gene as the cause of Huntington’s Disease (HD), abnormal energy metabolism and mitochondrial dysfunction had been suggested as a possible pathogenic mechanism in HD. These initial investigations described defects in energy metabolism using Positron Emission Tomography (PET) and Nuclear Magnetic Resonance (NMR) Spectroscopy in symptomatic and pre-symptomatic HD patients. Concurrently, 3-nitroproprionic acid, a mitochondrial complex II inhibitor, was found to replicate many of the pathological and clinical features of HD when administered to animals. Subsequently, reductions in mitochondrial respiratory chain enzyme activities in HD brain and muscle, HD mice models and cellular HD models were discovered and confirmed impaired mitochondrial function as an important component of pathogenesis. A unifying hypothesis linking chronic ATP depletion, oxidative stress and mitochondrial dysfunction culminated in the “slow excitotoxic theory” of HD pathogenesis. More recently, the localization of mutant htt within mitochondria and the association between transcriptional dysregulation caused by impaired PGC-1α activity with abnormal mitochondrial biogenesis and function has provided further links with additional potential pathogenic mechanisms.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Alam ZI, Halliwell B, Jenner P (2000) J Neurochem 75:840–846
Albin RL, Young AB, Penney JB, Handelin B, Balfour R, Anderson KD et al (1990) N Engl J Med 3322(18):1293–1298
Albin RL, Greenamyre JT (1992) Neurology 42(4):733–738
Alexi T, Hughes PE, Faull RL, Williams CE (1998) NeuroReport 9:R57–R64
Arenas J, Campos Y, Ribacoba R, Martin MA, Rubio JC, Ablanedo P, Cabello A (1998) Complex I defect in muscle from patients with Huntington’s disease. Ann Neurol 43:397–400
Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM et al (1993a) J Neurosci 13:4181–4192
Beal MF, Brouillet E, Jenkins BG, Henshaw R, Rosen BR, Hyman BT (1993b) J Neurochem 61:1147–1150
Beal MF, Henshaw DR, Jenkins BG, Rosen BR, Schulz JB (1994) Ann Neurol 36:882–888
Benchoua A, Trioulier Y, Zala D, Gaillard MC, Lefort N, Dufour N et al (2006) Mol Biol Cell 17(4):1652–1663
Bogdanov M, Ferrante RJ, Kuemmerle S, Klivenyi P, Beal MF (1998) J Neurochem 71:2642–2644
Brennan WA Jr, Bird ED, Aprille JR (1985) Regional mitochondrial respiratory activity in Huntington’s disease brain. J Neurochem 44:1948–1950
Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM et al (1997) Ann Neurol 41:646–653
Butterworth NJ, Williams L, Bullock JY, Love DR, Faull RL, Dragunow M (1998) Neuroscience 87:49–53
Chang DTW, Rintoul GL, Pandipati S, Reynolds I (2006) Neurobiol Dis 22:388–400
Choo YS, Johnson GVW, MacDonald M, Detloff PJ, Lesort M (2004) Hum Mol Genet 13:1407–1420
Chyi T, Chang C (1999) Neurosci 92:1035–1041
Cooper JM, Korlipara LV, Hart PE, Bradley JL, Schapira AH (2008) Coenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol 15:1371–1379
Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D (2006) Cell 127(1):59–69
Cull-Candy S, Brickley S, Farrant M (2001) Curr Opin Neurobiol 11:327–335
Dautry C, Conde F, Brouillet E, Mittoux V, Beal MF, Bloch G et al (1999) Neurobiol Dis 6:259–268
Dejean LM, Martinez-Caballero S, Kinnally KW (2006) Cell Death and Differentiation 13:1387–1395
Favit A, Nicoletti F, Scapagnini U, Canonico PL (1992) J Cereb Blood Flow Metab 12:638–645
Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK et al (2000) J Neurosci 20:4389–4397
Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF (2002) J Neurosci 22:1592–1599
Fukui H, Moraes CT (2007) Hum Mol Gen 16(7):783–797
Grafton ST, Mazziotta JC, Pahl JJ, St George-Hyslop P, Haines JL, Gusella J et al (1990) Ann Neurol 5:614–621
Greco A, Minghetti L, Levi G (2000) Neurochem Res 25:1357–1364
Gu M, Gash MT, Mann VM, Javoy-Agod F, Cooper JM, Schapira AH (1996) Mitochondrial defect in Huntington’s disease caudate nucleus. Ann Neurol 39(3):385–389
Harms L, Meierkord H, Timm G, Pfeiffer L, Ludolph AC (1997) J Neurol Neurosurg Psychiatry 62:27–30
Hart PE, Lodi R, Rajagopalan B, Bradley JL, Crilley JG, Turner C et al (2005) Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 62:621–626
Group HS (2001) Neurology 57:397–404
Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR (1993) Neurology 43:2689–2695
Jenkins BG, Rosas HD, Chen YCI, Makabe T, Myers R, MacDonald M et al (1998) Neurology 50:1357–1365
Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF (1997) Ann Neurol 41:160–165
Kuwert T, Lange HW, Langen K-J, Herzog H, Albrecht A, Feinendegen LE (1990) Brain 113:1405–1423
Kuwert T, Lange HW, Boecker H, Titz H, Herzog H, Aulich A et al (1993) J Neurol 241:31–36
La Fontaine MA, Geddes JW, Banks A, Butterfield DA (2000) Brain Res 858:356–362
Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S et al (2005) PLoS Biol 3:e101
Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O et al (2002) Nature 418:797–801
Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ et al (2000) Ann Neurol 48:72–76
Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri M (1991) Can J Neurol Sci 18:492–498
Mann VM, Cooper JM, Javoy-Agid F, Agid Y, Jenner P, Schapira AH (1990) Mitochondrial function and parental sex effect in Huntington’s disease. Lancet 336:749
Martin WRW, Clark C, Ammann W, Stoessl AJ, Shtybel W, Hayden MR (1992) Neurology 42:223–229
Martin WRW, Hanstock C, Hodder J, Allen JS (1996) Ann Neurol 40:538
Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R et al (1998) J Neurosci 18:156–163
McBride HM, Neuspiel M, Wasiak S (2006) Curr Biol 16(14):R551–R560
Milner DJ, Mavroidis M, Weisleder N, Capetanaki Y, Milner DJ (2000) J Cell Biol 150:1283–1298
Morgan-Hughes JA, Schapira AH, Cooper JM, Clark JB (1988) Molecular defects of NADH-ubiquinone oxidoreductase (complex I) in mitochondrial diseases. J Bioenerg Biomembr 20:365–382
Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK et al (1991) Arch Neurol 48:800–804
Owen AD, Schapira AH, Jenner P, Marsden CD (1996) Oxidative stress and Parkinson’s disease. Ann NY Acad Sci 786:217–223
Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ et al (2002) Nat Neurosci 5(8):731–736
Parker WD Jr, Boyson SJ, Luder AS, Parks JK (1990) Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington’s disease. Neurology 40(8):1231–1234
Patel M, Day BJ, Crapo JD, Fridowich I, McNamara JO (1996) Neuron 16:345–355
Perez-Severiano F, Rios C, Segovia J (2000) Brain Res 862:234–237
Petrasch-Parwez E, Nguyen HP, Lobbecke-Schumacher M, Habbes HW, Wieczorek S, Riess O et al (2007) J Comp Neurol 501(5):716–730
Pratley RE, Salbe AD, Ravussin E, Caviness JN (2000) Ann Neurol 47:64–70
Raymond L (2003) Clin Neurosci Res 3(3):121–128
Rizzuto R (2001) Curr Op Neurobiol 11:306–311
Sanchez-Pernaute R, Garcia-Segura JM, del Barrio Alba A, Viano J, de Yebenes JG (1999) Neurology 53:806
Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler JF Jr, Greenamyre JT, Snyder SH, Ross CA (1999) Increased apoptosis of Huntington disease lymphoblast associated with repeat length-dependent mitochondrial depolarization. Nat Med 5:1194–1198
Schapira AH (2006) Mitochondrial disease. Lancet 368:70–82
Schapira AH (1995) Oxidative stress in Parkinson’s disease. Neuropathol Appl Neurobiol 21:3–9
Schapira AH, Cooper JM, Morgan-Hughes JA et al (1988) Molecular basis of mitochondrial myopathies: polypeptide analysis in complex-I deficiency. Lancet 1:500–503
Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson M et al (2005) Hum Mol Genet 14:2871–2880
Solans A, Zambrano A, Rodríguez M, Barrientos A (2006) Hum Mol Genet 15(20):3063–3081
Stahl WL, Swanson PD (1974) Biochemical abnormalities in Huntington’s chorea brains. Neurology 24:813–819
Tabrizi SJ, Cleeter MWJ, Xuereb J, Taanman JW, Cooper JM, Schapira AHV (1999) Ann Neurol 45:25–32
Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G et al (2000) Ann Neurol 47:80–86
Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AH et al (2005) Neurology 64(9):1655–1656
Thomas PK, Cooper JM, King RH, Workman JM, Schapira AH, Goss-Sampson MA, Muller DP (1993) Myopathy in vitamin E deficient rats: muscle fibre necrosis associated with disturbances of mitochondrial function. J Anat 183:451–461
Turner C, Cooper JM, Schapira AH (2007) Clinical corralates of mitochondrial function in Huntington’s disease muscle. Mov Disord 22(12):1715–1721
Wyttenbach A, Swartz J, Kita H, Thykjaer T, Carmichael J, Bradley J et al (2001) Hum Mol Genet 10(17):1829–1845
Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P et al (2002) Neuron 33:849–860
Zeron MM, Fernandes HB, Krebs C, Shehadeh J, Wellington CL, Leavitt BR et al (2004) Mol Cell Neurosci 25:469–479
Author information
Authors and Affiliations
Corresponding author
Additional information
This review will briefly summarise the evidence for mitochondrial dysfunction in HD and how this may affect strategies for future treatments.
Rights and permissions
About this article
Cite this article
Turner, C., Schapira, A.H.V. Mitochondrial matters of the brain: the role in Huntington’s disease. J Bioenerg Biomembr 42, 193–198 (2010). https://doi.org/10.1007/s10863-010-9290-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10863-010-9290-y